U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07509086) titled 'IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia' on Feb. 21.
Brief Summary: This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.
Study Start Date: Dec. 29, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Multiple Myeloma
Plasma Cell Leukemia (PCL)
Intervention:
BIOLOGICAL: IL-15-armored CAR-T cells
BCMA-targeted: 1.0/1.5/2.0 x 10^6 CAR-T cells; CD19/BCMA dual-targeted: 1.0/1.5/2.0 x 10^...